Sheri Wilcox
About Sheri Wilcox
Sheri Wilcox VP of Probe Development and Bioinformatics
Sheri Wilcox serves as the Vice President of Probe Development and Bioinformatics. In this role, she oversees the development and implementation of advanced methodologies for probing biological systems. Her work is pivotal in harnessing bioinformatics to advance research and development, guide innovation, and streamline processes. The integration of probing technologies and bioinformatics under her leadership enhances the quality and efficiency of scientific investigations within the organization.
Sheri Wilcox and the SomaScan Platform
Sheri Wilcox played a crucial role in the development of the SomaScan Platform and SOMAmer reagents during her 21 years at SomaLogic. Her contributions were instrumental in advancing the company's capabilities in proteomics. The SomaScan Platform is a high-throughput aptamer-based proteomics platform that is utilized for biomarker discovery and clinical research. SOMAmer (Slow Off-rate Modified Aptamer) reagents are a key component of this platform, and Sheri Wilcox's leadership in their development was pivotal to the system's success.
Sheri Wilcox Research in Aptamers for Biomarker Discovery
Throughout her tenure at SomaLogic, Sheri Wilcox guided research focused on aptamers for biomarker discovery. She directed initiatives aimed at understanding and leveraging aptamers—short, single-stranded nucleic acids that bind to specific targets with high affinity. Her research contributed to significant advancements in the identification and characterization of biomarkers for various diseases, thus facilitating the development of diagnostic and therapeutic applications.
Sheri Wilcox’s Background in Chemistry and Structural Biology
Sheri Wilcox holds a B.S. in Chemistry from Vanderbilt University and earned her Ph.D. in Macromolecular and Cellular Structure and Chemistry from Scripps Research. Her educational background provided a strong foundation for her subsequent career in proteomics and bioinformatics. Additionally, her postdoctoral fellowship at Pharmacia—before its merger with Pfizer Inc.—further developed her expertise in the field, preparing her for a distinguished career in scientific research and development.